July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Quantitative Fundus Autofluorescence in PROM1-Macular Dystrophy
Author Affiliations & Notes
  • Maarjaliis Paavo
    Columbia University Medical Center, Ophthalmology , New York, New York, United States
    Helsinki University Eye Hospital, Finland
  • Winston Lee
    Columbia University Medical Center, Ophthalmology , New York, New York, United States
  • Jose R. Carvalho-Jr
    Columbia University Medical Center, Ophthalmology , New York, New York, United States
    Department of Ophthalmology, Federal University of Pernambuco, Brazil
  • Stephen Tsang
    Columbia University Medical Center, Ophthalmology , New York, New York, United States
    Department of Pathology and Cell Biology, Columbia University Medical Center, New York, United States
  • Rando Allikmets
    Columbia University Medical Center, Ophthalmology , New York, New York, United States
    Department of Pathology and Cell Biology, Columbia University Medical Center, New York, United States
  • Janet Sparrow
    Columbia University Medical Center, Ophthalmology , New York, New York, United States
    Department of Pathology and Cell Biology, Columbia University Medical Center, New York, United States
  • Footnotes
    Commercial Relationships   Maarjaliis Paavo, None; Winston Lee, None; Jose R. Carvalho-Jr, None; Stephen Tsang, None; Rando Allikmets, None; Janet Sparrow, None
  • Footnotes
    Support  RO1EY024091: P30EY019007
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5025. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maarjaliis Paavo, Winston Lee, Jose R. Carvalho-Jr, Stephen Tsang, Rando Allikmets, Janet Sparrow; Quantitative Fundus Autofluorescence in PROM1-Macular Dystrophy. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5025.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Mutations in PROMININ 1 (PROM1), a transmembrane glycoprotein, alter photoreceptor outer segment disk morphogenesis and can cause Stargardt-like macular dystrophy (STGD4; MIM603786) with fundus features similar to ABCA4-disease (recessive Stargardt disease, STGD1). As short wavelength fundus autofluorescence (SW-AF) is elevated in STGD1 we sought to quantify the levels of autofluorescence in STGD4 to seek a better understanding of the disease process.

Methods : Ten eyes of 7 patients (33-66 years, mean age = 49,4 years) were prospectively studied by clinical exam and multimodal imaging. Autofluorescence (AF) images were acquired with the Spectralis SLO-OCT (Heidelberg Eng.) modified by insertion of an internal AF reference to account for variable laser power and detector sensitivity for quantitative autofluorescence (qAF). Further clinical testing also included near-infrared autofluorescence (NIR-AF), spectral domain-optical coherence tomography (SD-OCT) and full-field electroretinography (ffERG). The genetic cause of the disease was confirmed by direct sequencing of the PROM1 gene (23 exons) in all patients.

Results : All patients presented with isolated lesions of macular atrophy, however one family with individuals affected across two generations exhibited granular fleck-like deposits across the posterior pole. Areas of granular deposition corresponded to intermittent loss of the EZ band while discrete regions of hypoautofluorescence corresponded to complete loss of outer retinal layers on SD-OCT. Four patients presented with foveal sparing. Autofluorescence levels within the macula (qAF8) the macula of all patients were found to be within the 95% confidence intervals of healthy age-matched individuals.

Conclusions : Although PROM1-macular dystrophy (STGD4) can exhibit phenotypic overlap with STGD1, significantly increased autofluorescence levels are not detected. As such, lipofuscin accumulation may not be a significant event in the pathophysiology of PROM1-disease. The qAF approach could serve as a method of early differential diagnosis when considering different types of macular dystrophy. qAF will help to identify appropriate disease targets as therapeutics become available to treat retinal disease.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×